华恒生物股东拟减持3%股份，赴港IPO申请已提交

Group 1 - The fourth largest shareholder of Huaheng Biological plans to reduce its holdings by no more than 3.252 million shares, accounting for 3% of the total share capital, due to the shareholder's own business needs [1][2] - The reduction will be executed through centralized bidding and block trading, with the specific progress of the reduction to be disclosed later [2] Group 2 - Huaheng Biological has submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds for global business expansion, new product development, capacity upgrades, and working capital [1][3] - The IPO process may impact the company's capital structure and market attention [3]